Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH)-Reference-Cited by-同舟云学术

Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH)

Published:2018-11 Issue:9 Volume:41 Page:597-608
ISSN:0210-5705
Container-title:Gastroenterología y Hepatología
language:es
Short-container-title:Gastroenterología y Hepatología

Author:

Calleja Jose L.,Macias Juan,Forns Xavier,Garcia Federico,Berenguer Marina,Garcia Deltoro Miguel,Buti Maria,Granados Rafael,Carrion Jose A.,Morano Luis,Fernandez Inmaculada,Coste Pablo,Pineda Juan A.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference56 articles.

1. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial;Zeuzem;Ann Intern Med,2015

2. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection;Kwo;Gastroenterology,2017

3. EASL Recommendations on Treatment of Hepatitis C 2018;J Hepatol.,2018

4. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection;Zeuzem;N Engl J Med,2018

5. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial;Forns;Lancet Infect Dis,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocolo diagnóstico de la fiebre con hipertransaminasemia en el paciente inmunocomprometido;Medicine - Programa de Formación Médica Continuada Acreditado;2024-05

2. Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years;Gastroenterología y Hepatología;2024-05

3. Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals;Atherosclerosis;2023-06

4. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review;Gastroenterología y Hepatología;2023-05

5. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review;Gastroenterología y Hepatología (English Edition);2023-05